Harnessing the Power of
Naturally Occurring NK Cells
to Fight Cancer and
Autoimmune Diseases

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases.

Harnessing the Power of Naturally Occurring NK Cells to Fight Cancer

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer.

ABOUT US

Indapta is a biotechnology company harnessing the natural power of the immune system to fight cancer and autoimmune diseases with its universal natural killer (NK) cell platform derived from healthy donors. The company’s allogeneic platform is based on a subset of NK cells that are deficient in the FceR1g protein, and are called g-NK cells (g minus NK cells). These cells are particularly potent at killing cancer cells and autoreactive T and B cells. Indapta is working to bring this off-the-shelf cellular therapy to  patients with cancer and autoimmune diseases to address the limitations of currently available therapies. Indapta is based in Houston, TX, and Seattle, WA.

G-NK cell therapy has potent activity alone or combined with FDA-approved tumor-targeting antibodies.

G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies.

LEADERSHIP

SCIENCE AND PLATFORM

Cancer and autoimmune diseases are leading causes of death and morbidity worldwide. Current therapies are suboptimal, frequently ineffective and often cause significant side effects.

Immunotherapies are a formidable new mechanism to fight cancer. Designed to boost the immune response, immunotherapies such as G-NK therapy are being developed to address the limitations of currently available autologous T-cell therapies. In addition, g-NK cells have a unique mechanism to delete the autoreactive T and B cells that are responsible for autoimmune diseases. They provide an opportunity to transform the treatment for these diseases.

 
Indapta is developing a universal, allogeneic NK cell therapy designed to substantially improve the treatment of both cancer and autoimmune diseases. Engineered by nature to eliminate abnormal cells, Indapta’s NK cell platform is based on a naturally occurring subset of natural killer cells known as g-NK cells that that have undergone epigenetic changes including the down-modulation of the FceR1γ chain. Compared to conventional NK cells, g-NK cells demonstrate increased cytokine secretion, higher levels of cytolytic enzymes, a more favorable metabolic profile, increased persistence, and markedly higher antibody dependent cell mediated cytotoxicity (ADCC).
 
Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies. In addition, scientists have demonstrated that naturally occurring g-NK cells have a profound ability to reduce the risk of developing multiple sclerosis in high risk individuals, as well as slow the progression of multiple sclerosis in those with the disease. 
 
Indapta has developed a proprietary process to expand g-NK cells that yields a highly potent product without the need for artificial genetic engineering. In the company’s first-in-human Phase 1 trial, patients with relapsed/refractory non-Hodgkin’s lymphoma and multiple myeloma patients are being treated with g-NK cells in combination with FDA approved monoclonal antibodies. In addition the company is conducting a Phase 1 trial of g-NK cells in patients with multiple sclerosis.
 
play-sharp-fill


EXPANDED ACCESS POLICY

Indapta’s Expanded Access Policy (EAP) covers the use of its investigational products outside of an ongoing clinical trial. Indapta appreciates the need for additional treatments for patients who have serious or immediately life-threatening diseases and have limited available treatment options. The decision to establish an EAP is dependent on a number of key factors consistent with the US Food and Drug Administration (FDA) and other regulatory agencies’ requirements. These include, but are not limited, to the following: 

• The illness for which the investigational cell therapy is being considered must be serious or life-threating, with no other satisfactory treatment options (such as approved products or enrolling clinical trials); 

• There is sufficient evidence that the potential benefit of the investigational drug to the patient would outweigh the potential risks, based on all available safety and efficacy information; and 

• Providing the investigational cellular immunotherapy as part of an EAP will not interfere with the enrollment of clinical trials to support the development and marketing approval. Based on these factors and the early stage of clinical development for our products, Indapta believes that participation in our clinical trials is the appropriate means to access our investigational cellular immunotherapies. 

Therefore, Indapta does not currently have an expanded access program. If you are a patient seeking access to our investigational product(s), please contact your treating healthcare provider. 

For more information about our ongoing clinical trials, please refer to www.clinicaltrials.gov, study number NCT06119685. Healthcare providers who are interested in learning more about clinical program(s) and investigational product(s) and/or participation in our clinical trial(s), please contact trials@indapta.com.

RECENT NEWS

CORPORATE PRESENTATION

Slides

Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.

PUBLICATIONS

Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.

PEER
REVIEWED
AACR 2025
CLINICAL & TRANSLATIONAL
SITC 2024
PRECLINICAL
MOA
SITC 2024
PRECLINICAL
ONCOLOGY

Careers

Become a part of our dynamic team at Indapta Therapeutics and embark on an exciting journey. Join us in making a meaningful impact on the lives of patients worldwide through innovative therapies and cutting-edge science